Cabaletta Bio (CABA) Projected to Post Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 20th. Analysts expect Cabaletta Bio to post earnings of ($0.66) per share for the quarter.

Cabaletta Bio Trading Up 6.7 %

Shares of NASDAQ:CABA opened at $1.91 on Thursday. The firm’s 50 day moving average is $2.28 and its two-hundred day moving average is $3.27. The firm has a market capitalization of $93.36 million, a P/E ratio of -0.89 and a beta of 2.58. Cabaletta Bio has a 52 week low of $1.59 and a 52 week high of $21.24.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Wells Fargo & Company cut shares of Cabaletta Bio from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $12.00 to $6.00 in a report on Thursday, December 19th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a report on Friday, November 29th. Evercore ISI cut shares of Cabaletta Bio from an “outperform” rating to an “inline” rating and decreased their price objective for the company from $15.00 to $6.00 in a report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, February 18th. Finally, William Blair restated an “outperform” rating on shares of Cabaletta Bio in a report on Monday, November 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $22.71.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.